华大智造（ [Table_StockNameRptType] 688114） 公司点评 2024 年收入平稳增长，国产替代加速 | [Table_Rank] | 投资评级：买入（维持） | | | --- | --- | --- | | 报告日期： | 2025-05-07 | | | [Table_BaseData] 收盘价（元） | | 81.02 | | 近 12 个月最高/最低（元） | | 106.66/ | | | | 34.68 | | 总股本（百万股） | | 417 | | 流通股本（百万股） | | 213 | | 流通股比例（%） | | 51.12 | | 总市值（亿元） | | 337 | | 流通市值（亿元） | | 173 | [公司价格与沪深 Table_Chart] 300 走势比较 -48% -16% 17% 49% 81% 5/24 8/24 11/24 2/25 5/25 华大智造 沪深300 [Table_Author] 分析师：谭国超 执业证书号：S0010521120002 邮箱：tangc@hazq.com 分析师：李婵 执业证书号：S0010523120002 ...

机构行为的十大伪规律 报告日期： 2025-05-06 [Table_Author] 首席分析师：颜子琦 [Table_IndNameRptType]2 固定收益 专题报告 第四，基金卖出就是"赎回潮"吗？——历史上看未必。由于 2024 年至今是 债券市场的大牛市，但每一次回调都相对快速，利率上行时市场总会产生"赎 回潮"的隐忧，而从数据上看基金也确实是多次行情的主要砸盘力量，但基金 的卖出行为不等于赎回潮，本文提供了两个思路进行辅助证明。 第五，保险都是配置盘吗？——交易盘比重已明显提升。通常我们认为，银行 与保险机构是债券市场中的两大类配置盘，而保险机构的行为又主要以超长 债配置为主，近年来由 30Y 国债逐步转向 30Y 地方债，但研究后我们发现， 2024 年以来保险机构中交易盘的占比已经明显攀升，可通过卖出数据辅以证 明。 执业证书号：S0010522030002 电话：13127532070 邮箱：yanzq@hazq.com [Table_Author] 研究助理：洪子彦 执业证书号：S0010123060036 电话：15851599909 邮箱：hongziyan@hazq.com 主要观 ...

[Table_StockNameRptType] 中密控股（300470） 公司点评 24 年报+25Q1 点评：业绩符合预期，25Q1 归母净利同比+13.84% | [Table_Rank] 投资评级：买入（维持） | | | --- | --- | | 报告日期： | 2025-05-06 | | [Table_BaseData] 收盘价（元） | 36.07 | | 近 12 个月最高/最低（元） | 45.18/31.51 | | 总股本（百万股） | 208 | | 流通股本（百万股） | 197 | | 流通股比例（%） | 94.8% | | 总市值（亿元） | 75.09 | | 流通市值（亿元） | 71.25 | [公司价格与 Table_Chart] 沪深 300 指数走势比较 -30% -20% -10% 0% 10% 20% 30% 中密控股 沪深300 [分析师： Table_Author] 张帆 执业证书号：S0010522070003 邮箱： zhangfan@hazq.com 分析师： 陶俞佳 执业证书号：S0010524100004 邮箱：taoyujia@hazq.co ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved double-digit growth in both revenue and profit for 2024, with a notable increase in non-recurring net profit growth [2][3] - The company's revenue for 2024 reached 1.203 billion yuan, a year-on-year increase of 14.75%, while the net profit attributable to shareholders was 254 million yuan, up 15.95% year-on-year [2] - The first quarter of 2025 showed a slight decline in revenue and profit, indicating some pressure on performance [2][3] Financial Performance - In 2024, the company reported a gross margin of 41.88%, an increase of 0.56 percentage points year-on-year, with a total expense ratio of 11.81%, down 1.49 percentage points [4] - The blood products segment generated revenue of 1.072 billion yuan in 2024, a year-on-year increase of 8.80%, with a gross margin of 43.04% [5] - The company’s plasma collection volume increased by 8.7% in 2024, reaching 562 tons [5][8] Future Projections - Revenue projections for 2025, 2026, and 2027 are 1.347 billion yuan, 1.497 billion yuan, and 1.653 billion yuan, respectively, with year-on-year growth rates of 12.0%, 11.1%, and 10.4% [9][10] - The net profit attributable to shareholders is expected to be 299 million yuan, 345 million yuan, and 396 million yuan for 2025, 2026, and 2027, respectively, with growth rates of 18.0%, 15.3%, and 14.8% [9][10]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved double-digit growth in both revenue and profit for 2024, with a notable increase in non-recurring net profit growth [2][3] - The company reported a revenue of 1.203 billion yuan for 2024, representing a year-on-year increase of 14.75%, and a net profit attributable to shareholders of 254 million yuan, up 15.95% year-on-year [2] - The non-recurring net profit reached 264 million yuan, showing a significant year-on-year growth of 25.97% [2] - In Q1 2025, the company experienced a slight decline in revenue and net profit, with revenue at 225 million yuan, down 0.57% year-on-year, and net profit at 44 million yuan, down 6.54% year-on-year [2] Financial Performance - The company maintained a gross margin of 41.88% in 2024, an increase of 0.56 percentage points year-on-year [4] - The operating cash flow net amount was 178 million yuan, a decrease of 55.33% year-on-year, primarily due to reduced cash received from sales and increased cash outflows [4] - The blood products segment generated revenue of 1.072 billion yuan in 2024, up 8.80% year-on-year, with a gross margin of 43.04%, an increase of 2.28 percentage points [5] - The company’s core products, including human albumin and immunoglobulin, showed strong performance with revenues of 459 million yuan and 431 million yuan, respectively, both reflecting year-on-year growth of over 15% [5] Future Outlook - The company is expected to achieve revenues of 1.347 billion yuan, 1.497 billion yuan, and 1.653 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 12.0%, 11.1%, and 10.4% [9] - The net profit attributable to shareholders is projected to be 299 million yuan, 345 million yuan, and 396 million yuan for the same years, with growth rates of 18.0%, 15.3%, and 14.8% [9] - The company’s valuation is estimated at 21X, 18X, and 16X for the years 2025, 2026, and 2027, respectively [9]

[Table_Chart] 公司价格与沪深 300 走势比较 -40% -20% 0% 20% 4/29 6/29 8/29 10/2912/29 2/28 新凤鸣 沪深300 [Table_Author] 分析师：王强峰 [Table_Author] 分析师：王强峰 [Table_StockNameRptType] 新凤鸣（603225） 公司点评 产销稳步提升，PTA 项目投产一体化程度加深 | 投资评级：买入（维持） [Table_Rank] | | | | --- | --- | --- | | 报告日期： | 2025-05-05 | | | [Table_BaseData] 收盘价（元） | | 10.84 | | 近 12 个月最高/最低（元） | | 15.86/9.59 | | 总股本（百万股） | | 1,525 | | 流通股本（百万股） | | 1,512 | | 流通股比例（%） | | 99.15 | | 总市值（亿元） | | 165 | | 流通市值（亿元） | | 164 | 执业证书号：S0010522110002 电话：13621792701 邮箱：wangqf@hazq ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a steady growth in performance, with a net profit of 289 million yuan in 2024, representing a year-on-year increase of 9.58%. For Q1 2025, the net profit was 69 million yuan, up 0.23% year-on-year, aligning with expectations [4][5] - The company achieved a revenue of 1.357 billion yuan in 2024, a year-on-year increase of 1.03%, and the revenue for Q1 2025 grew by 1.89% year-on-year, indicating ongoing progress in its three-tier business strategy [5][6] Summary by Sections Business Segments 1. **First Tier Business**: This includes core components for turbochargers and various precision parts, which serve as the company's stable foundation. In 2024, the turbocharger business generated 1.058 billion yuan in revenue, with a CAGR of 9.83% from 2022 to 2024, accounting for 77.9% of total revenue. The gross margin for the automotive parts segment reached 33.68%, up 0.31 percentage points year-on-year [5] 2. **Second Tier Business**: Focused on components for electric vehicles, this segment saw significant growth, with sales revenue of 184 million yuan in 2024, a year-on-year increase of 38.73%. The company has successfully launched its subsidiary for electric vehicle components, enhancing its competitive position [6] 3. **Third Tier Business**: This includes areas such as "industrial mother machines," "humanoid robots," and "smart connected vehicles." The company has achieved successful validation and application of its high-precision rolling screw nuts and linear guide products, with small batch orders being delivered in 2024 [6] Financial Performance - The company's gross margin improved to 34.7% in 2024, up 0.24 percentage points year-on-year, while the net margin reached 21.29%, an increase of 0.53 percentage points [7] - Revenue forecasts for 2025-2027 are adjusted to 1.531 billion, 1.751 billion, and 2.015 billion yuan respectively, with net profits projected at 333 million, 385 million, and 451 million yuan [8][10] - The diluted EPS for 2025-2027 is expected to be 0.67, 0.77, and 0.90 yuan, with corresponding PE ratios of 41.7, 36.1, and 30.8 [8][10]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a steady growth in performance, with a 9.58% year-on-year increase in net profit to 289 million yuan for 2024, and a 0.23% increase in Q1 2025 net profit to 69 million yuan, meeting expectations [4][5] - The company achieved a revenue of 1.357 billion yuan in 2024, reflecting a 1.03% year-on-year growth, supported by the robust performance of the automotive industry, particularly in the new energy vehicle sector [5][6] Summary by Sections Business Segments 1. **First-tier Business**: This includes core components for turbochargers and various precision parts, which serve as the foundation for stable development. The turbocharger business generated 1.058 billion yuan in revenue, with a CAGR of 9.83% from 2022 to 2024, accounting for 77.9% of total revenue [5] 2. **Second-tier Business**: Focused on new energy vehicle components, this segment saw significant growth with sales revenue of 184 million yuan and a 38.73% increase in sales volume to 9.1077 million units in 2024, benefiting from the overall rise in new energy vehicle production and sales [6] 3. **Third-tier Business**: This includes areas such as "industrial mother machines," "humanoid robots," and "intelligent connected vehicles." The company has successfully validated its high-precision rolling screw nuts and linear guide products with well-known domestic machine tool manufacturers, achieving small batch orders in 2024 [6] Financial Performance - The company's gross margin reached 34.7% in 2024, a year-on-year increase of 0.24 percentage points, while the net margin was 21.29%, up 0.53 percentage points [7] - Revenue forecasts for 2025-2027 are adjusted to 1.531 billion yuan, 1.751 billion yuan, and 2.015 billion yuan respectively, with net profits projected at 333 million yuan, 385 million yuan, and 451 million yuan [8][10] Valuation Metrics - The projected diluted EPS for 2025-2027 is 0.67 yuan, 0.77 yuan, and 0.90 yuan, with corresponding PE ratios of 41.7, 36.1, and 30.8 [8][10] - The company is positioned as a leading player in precision components, with significant growth potential in the new energy vehicle and industrial sectors, justifying the "Buy" rating [8]

沪硅产业(688126) 公司点评 沪硅产业：300mm 硅片持续扩产，利润端短期承压 投资评级:增持(维持) 报告日期:2025-04-30 | 收盘价（元） | 17.43 | | --- | --- | | 近 12 个月最高/最低（元） | 27.34/12.41 | | 总股本（百万股） | 2747 | | 流通股本(百万股) | 2720 | | 流通股比例 (%) | 99.02 | | 总市值(亿元) | 478.8 | | 流通市值 (亿元) | 474.1 | 公司价格与沪深 300 走势比较 1/25 沪深300 分析师:陈耀波 执业证书号: S0010523060001 邮箱:chenyaobo@hazq.com 分析师:李元晨 执业证书号: S0010524070001 邮箱：liyc@hazq.com 相关报告 ● 投资建议 1. 300mm 硅片出货拐点对冲复苏低 预期 20241105 主要观点: ● 事件点评:沪硅产业发布 2024年度及 2025 第一季度报告 公司 2024 年实现营业收入约 33.9 亿元,同比增长约 6.2%;实现归母 净利润约-9.7 亿元，同比下 ...

| 华安研究 2025年5月金股组合 | 归母净利润（百万） | 归母净利润增速 | 营业收入（百万） | 营业收入增速 | eps | pe(pb有说明) | 行业 | 金股代码 | 金股 | 核心推荐逻辑 | 风险提示 | 研究员 | 报告依据 | | | | | | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2023A | 2024A/E | 2025E | 2023A | 2024A/E | 2025E | 2023A | 2024A/E | 2025E | 2023A | 2024A/E | 2025E | 2 ...